Topic Hub
20 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 20 of 20 clinical reviews.
Semaglutide (Ozempic) 0.5-2.0 mg is being explored off-label for heart failure. Review the dosing protocol, trial evidence from SELECT and STEP-HFpEF, FDA-approved indications, and what clinicians should know.
Read clinical reviewA physician-reviewed summary of the clinical trial evidence, off-label status, GRADE ratings, and practical considerations for using semaglutide (Ozempic 0.5 to 2.0 mg) in heart failure patients.
Read clinical reviewSemaglutide (Ozempic) is not FDA-approved for heart failure, but emerging trial data in HFpEF shows measurable benefits. Learn the evidence, monitoring protocols, and safety considerations for off-label use.
Read clinical reviewA clinical review of using semaglutide (Ozempic 0.5-2.0 mg) off-label for heart failure, including trial data, safety signals, and how it compares to FDA-approved HFpEF therapies.
Read clinical reviewA physician-reviewed evidence summary on using Ozempic (semaglutide 0.5 to 2.0 mg) off-label for kidney protection, including trial data, GRADE ratings, dosing considerations, and clinical guidance.
Read clinical reviewCan Ozempic (semaglutide 0.5 to 2.0 mg) protect the kidneys? A full clinical review of the FLOW trial, off-label prescribing rationale, GRADE evidence levels, and the monitoring protocol your nephrologist should follow.
Read clinical reviewSemaglutide (Ozempic) 0.5-2.0 mg is being studied for kidney protection in CKD. Review the off-label evidence, dosing protocols, FLOW trial results, and clinical guidance for renal use.
Read clinical reviewA clinical review of semaglutide (Ozempic) for kidney protection, including FLOW trial data, off-label considerations, dosing, risks, and what the evidence actually supports.
Read clinical reviewClinical evidence review of off-label semaglutide (Ozempic 0.5-2.0 mg) for nonalcoholic steatohepatitis (NASH), including trial data, dosing, and guideline positioning.
Read clinical reviewSemaglutide (Ozempic) 0.5 to 2.0 mg is used off-label for NASH. Review the dosing protocol, key trial data, FDA status, and what clinicians should know before prescribing.
Read clinical reviewSemaglutide (Ozempic) is not FDA-approved for NASH/MASH, but clinical trial data shows histological improvement in liver fibrosis and steatohepatitis. Learn the risks, dosing, and evidence.
Read clinical reviewA clinician-reviewed guide to using semaglutide (Ozempic 0.5 to 2.0 mg) off-label for NASH, covering the evidence base, GRADE ratings, required monitoring, and what FDA approval means for this indication.
Read clinical reviewComplete guide to monitoring requirements when using Ozempic (semaglutide 0.5-2.0 mg) off-label for PCOS, including lab schedules, safety parameters, and clinical endpoints.
Read clinical reviewSemaglutide (Ozempic) is used off-label for PCOS to improve insulin resistance, restore ovulation, and reduce androgen levels. Learn the dosing protocol, evidence base, and what clinicians should discuss with patients.
Read clinical reviewA clinician-reviewed evidence summary of off-label semaglutide (Ozempic) for polycystic ovary syndrome (PCOS), covering trial data on weight, androgens, ovulation, and insulin resistance.
Read clinical reviewA physician-reviewed deep dive into using semaglutide (Ozempic 0.5 to 2.0 mg) off-label for polycystic ovary syndrome. Covers the clinical evidence, GRADE ratings, FDA approval context, dosing, risks, and when to consider Wegovy or metformin instead.
Read clinical reviewOzempic (semaglutide 0.5-2.0 mg) is FDA-approved for type 2 diabetes, not weight loss. Here's what the clinical trials show about off-label use, real risks, and how it compares to the approved weight-loss dose.
Read clinical reviewOzempic (semaglutide 0.5 to 2.0 mg) is FDA-approved for type 2 diabetes, not weight loss. This clinician-reviewed guide covers the evidence, off-label dosing protocols, risks, and how it compares to FDA-approved Wegovy for weight management.
Read clinical reviewOzempic (semaglutide 0.5-2.0 mg) is FDA-approved for type 2 diabetes but widely prescribed off-label for weight loss. Learn the evidence, proper monitoring, and clinical protocols.
Read clinical reviewA clinical evidence summary of off-label semaglutide (Ozempic 0.5 to 2.0 mg) for weight loss, including trial data, FDA status, dosing, and how it compares to on-label Wegovy.
Read clinical review